378 related articles for article (PubMed ID: 26846108)
1. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
3. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype.
Zelivianski S; Verni M; Moore C; Kondrikov D; Taylor R; Lin MF
Biochim Biophys Acta; 2001 May; 1539(1-2):28-43. PubMed ID: 11389966
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
5. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
Song Y; Wu G; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
[TBL] [Abstract][Full Text] [Related]
6. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
8. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.
Fraser JA; Sutton JE; Tazayoni S; Bruce I; Poole AV
Sci Rep; 2019 Dec; 9(1):19076. PubMed ID: 31836808
[TBL] [Abstract][Full Text] [Related]
9. Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-κB transactivation in LNCaP cells.
Dasari C; Yaghnam DP; Walther R; Ummanni R
Tumour Biol; 2017 May; 39(5):1010428317698382. PubMed ID: 28466782
[TBL] [Abstract][Full Text] [Related]
10. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
11. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
12. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.
Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N
Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
[TBL] [Abstract][Full Text] [Related]
14. Tumor protein D52 (isoform 3) induces NF-κB - STAT3 mediated EMT driving neuroendocrine differentiation of prostate cancer cells.
Sruthi KK; Natani S; Ummanni R
Int J Biochem Cell Biol; 2024 Jan; 166():106493. PubMed ID: 37935328
[TBL] [Abstract][Full Text] [Related]
15. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case n
Fromont G
Ann Pathol; 2017 Jun; 37(3):249-253. PubMed ID: 28522124
[No Abstract] [Full Text] [Related]
16. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
18. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.
Terry S; Maillé P; Baaddi H; Kheuang L; Soyeux P; Nicolaiew N; Ceraline J; Firlej V; Beltran H; Allory Y; de la Taille A; Vacherot F
Neoplasia; 2013 Jul; 15(7):761-72. PubMed ID: 23814488
[TBL] [Abstract][Full Text] [Related]
19. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
20. [Prostate cancer and apoptosis].
Mayora A; Arvelo F
Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
